OCERA THERAPEUTICS,INC. (NASDAQ:OCRX) Files An 8-K Results of Operations and Financial ConditionItem 9.01 Results of Operations and Financial Condition.
On August 1, 2017, Ocera Therapeutics,Inc. issued a press release announcing its financial results and other information for the quarter ended June 30, 2017. The full text of the press release and the related attachments are furnished as Exhibit99.1 hereto and incorporated herein by reference.
The information under this Item 9.01, including Exhibit99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
ExhibitNo. |
Description |
|
99.1 |
Press Release of Ocera Therapeutics, Inc. dated August 1, 2017, furnished hereto. |
Ocera Therapeutics, Inc. ExhibitEX-99.1 2 exhibit991oceraearningsrel.htm EXHIBIT 99.1 Exhibit Exhibit 99.1PRESS RELEASEOcera Therapeutics Reports Second Quarter 2017 Financial Results REDWOOD CITY,…To view the full exhibit click here
About OCERA THERAPEUTICS,INC. (NASDAQ:OCRX)
Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.
